Home / Stock ratings / SYK

Stock rating · Surgical & Medical Instruments & Apparatus

Stryker Corporation (SYK) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Stryker Corporation 55 out of 100 (Very Promising). Its highest factor score is risk-adjusted profile at 75, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

SYK · composite score

55/100
Very Promising
Nov 20
Rating date
Live price in the app →
Quality69
Momentum46
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About Stryker Corporation

Stryker designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices, including hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. It is among the three largest competitors in reconstructive orthopedic implants and the leader in operating room equipment. About a fourth of its total revenue comes from outside the US.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why SYK scores 55/100

SYK's 8 factor scores run from 36 to 75, and 3 of them sit above its composite of 55. Here is how SYK breaks down.

Valuation52/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 19.0x, earnings growth accelerating
Business quality69/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 65%
Price momentum46/100

Direction and relative strength of the recent share-price trend.

  • Price +4.8% above 50-day MA
Earnings track record52/100

History of beating or missing estimates, and where estimates are heading.

Analyst sentiment66/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How SYK compares

As of November 20, 2026, Stryker Corporation ranks 8th of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 62.

All stock rating pages.

Key risks for SYK

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Stryker Corporation sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds SYK's momentum and catalyst factors above.

SYK trade plan (Pro)

MELANY has a full position plan for Stryker Corporation: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates SYK

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Stryker Corporation's 55/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about SYK

Is Stryker Corporation (SYK) a buy?

As of 2026-11-20, MELANY rated Stryker Corporation Very Promising with a composite score of 55/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does SYK rank against similar companies?

As of November 20, 2026, Stryker Corporation ranks 8th of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 62. Among the other names in the group, the highest scores belong to DXCM (69) and TFX (67).

Should I buy Stryker Corporation stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Stryker Corporation (SYK) Very Promising with a composite of 55/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the SYK stock price forecast?

MELANY does not publish price targets or forecasts for SYK. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 55/100 across eight factors for Stryker Corporation, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for SYK as of 2026-11-20: its analyst sentiment factor is 66/100, and its price momentum factor is 46/100.

Is SYK stock overvalued or undervalued?

MELANY's valuation factor currently reads 52/100 for Stryker Corporation, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SYK's read.

What price should I buy SYK at?

Rather than chasing the current price, MELANY computes a smart entry zone for SYK: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying SYK stock?

The top risks MELANY currently flags for Stryker Corporation: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Stryker Corporation a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 69/100 for Stryker Corporation, and earnings track record, at 52/100. The 55/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will SYK stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 46/100 for SYK right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this SYK rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores SYK as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, SYK included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.